NCT05196295View on ClinicalTrials.gov

To Evaluate the Safety of Treating Rheumatologic and Metabolic Patients With Molecular Hydrogen Supplement.

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 11, 2022

Primary Completion Date

July 30, 2022

Study Completion Date

July 30, 2022

Conditions
Autoimmune DiseasesMetabolic Disease
Interventions
DRUG

Hydrogen

Participants take either 1 (n=5), 3 (n=5) or 6 (n=5) capsules every day for one month.

Trial Locations (1)

Unknown

RECRUITING

Min-Sheng Gereral hospital, Taoyuan District

Sponsors

Lead Sponsor

HoHo Biotech
All Listed Sponsors
lead

HoHo Biotech

INDUSTRY